ARK Investment Management Boosts Stake in Veracyte

Biotech firm sees increased institutional investment as it expands diagnostic offerings

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

ARK Investment Management LLC has increased its stake in Veracyte, Inc. (NASDAQ:VCYT) by 17.5% in the third quarter, according to a recent SEC filing. The investment firm now owns approximately 5.65% of the biotechnology company's shares, valued at $153.3 million. Veracyte develops and commercializes genomic tests to aid in the diagnosis of thyroid, lung, and other diseases.

Why it matters

The increased investment from ARK, a prominent institutional investor focused on innovative technologies, signals growing confidence in Veracyte's growth potential as it expands its portfolio of genomic diagnostic tests. This could help drive further institutional and retail investor interest in the company.

The details

According to the SEC filing, ARK Investment Management added 665,686 shares of Veracyte during the third quarter, bringing its total stake to 4,465,775 shares. Veracyte's stock has seen significant volatility over the past year, trading between a 52-week low of $22.61 and a high of $50.71. The company has been working to expand its menu of genomic tests, which currently focus on thyroid, lung, and other disease areas.

  • ARK Investment Management increased its stake in Veracyte during the third quarter of 2026.
  • Veracyte's stock has traded between $22.61 and $50.71 over the past 52 weeks.

The players

ARK Investment Management LLC

A prominent institutional investor focused on innovative technologies that has increased its stake in Veracyte, Inc.

Veracyte, Inc.

A biotechnology company that develops and commercializes genomic tests to aid in the diagnosis of thyroid, lung, and other diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The increased investment from ARK Investment Management in Veracyte signals growing institutional confidence in the company's ability to capitalize on the expanding market for genomic diagnostic tests. As Veracyte continues to diversify its product portfolio, it could attract further interest from investors seeking exposure to innovative healthcare technologies.